Alere (ALRPRB.PFD) Change In Receivables : $63.05 Mil (TTM As of Jun. 2017)

View and export this data going back to 2008. Start your Free Trial

What is Alere Change In Receivables?

Alere's change in receivables for the quarter that ended in Jun. 2017 was $13.63 Mil. It means Alere's Accounts Receivable declined by $13.63 Mil from Mar. 2017 to Jun. 2017 .

Alere's change in receivables for the fiscal year that ended in Dec. 2016 was $26.70 Mil. It means Alere's Accounts Receivable declined by $26.70 Mil from Dec. 2015 to Dec. 2016 .

Alere's Accounts Receivable for the quarter that ended in Jun. 2017 was $377.96 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Alere's Days Sales Outstanding for the three months ended in Jun. 2017 was 61.84.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Alere's liquidation value for the three months ended in Jun. 2017 was $-2,848.09 Mil.

Alere Change In Receivables Historical Data

The historical data trend for Alere's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alere Change In Receivables Chart

Alere Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Change In Receivables

Get a 7-Day Free Trial

-19.81

-41.31

-4.26

-6.68

26.70

Alere Quarterly Data
	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17
Change In Receivables	Get a 7-Day Free Trial															28.31	11.68	4.65	33.11	13.63

Alere Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $63.05 Mil.

Alere (NYSE:ALRPRB.PFD) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Alere's Days Sales Outstanding for the quarter that ended in Jun. 2017 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	377.963	/	557.672	*	91
=	61.84

2. In Ben Graham's calculation of liquidation value, Alere's accounts receivable are only considered to be worth 75% of book value:

Alere's liquidation value for the quarter that ended in Jun. 2017 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	491.849	-	3791.262	+	0.75 * 377.963	+	0.5 * 335.71
=	-2,848.09

Alere Change In Receivables Related Terms

Thank you for viewing the detailed overview of Alere's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Alere (ALRPRB.PFD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Alere Inc (NYSE:ALRPRB.PFD) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.alere.com

Alere, Inc. develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.

Executives

John Bridgen	officer: Sr VP, Business Development	51 SAWYER ROAD, C/O INVERNESS MEDICAL INNOVATIONS INC, WALTHAM MA 02453
Geoffrey S Ginsburg	director	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Renuka Uppaluri	officer: Senior VP, Global R&D	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mark Gladwell	officer: Senior VP, Global Operations	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Gregg J Powers	director	C/O QUANTUM CORPORATION, 224 AIRPORT PARKWAY SUITE 300, SAN JOSE CA 95110
Jonathan Wygant	officer: VP, Controller, CAO	3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Thomas Mckillop	director	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Melissa Guerdan	officer: SVP, Global Quality & Reg.	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Daniella Cramp	officer: Global Pres., Cardiometabolic	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Sanjay Malkani	officer: Global Pres., Toxicology	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
James Jr. Roosevelt	director	51 SAWYER ROAD, SUITE 200, HOPKINTON MA 02453
Robert Bernard Hargadon	officer: SVP, Global Human Resources	4327 LAKE WASHINGTON BLVD NE #6208, KIRKLAND WA 98033
John F Levy	director	C/O INNVERNESS MEDICAL INNOVATIONS, INC., 51 SAWYER ROAD, WALTHAM MA 02453
John Quelch	director	C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYER RD, WALTHAM MA 02453
Carol R Goldberg	director	C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYERS RD, WALTHAM MA 02453